Follistatin-344
Fat LossMyostatin-binding glycoprotein / researchExperimental
Isoform of follistatin that binds myostatin/activin. Gene-therapy and research-peptide forms exist; no FDA-approved follistatin drug. WADA prohibits myostatin inhibitors (S4).
For research use only.
Key Facts
- CAS
- 1461868-87-4
- Molecular Weight (MW)
- โ38โ40 kDa (glycosylation dependent)
- Half-life
- Varies; protein biologic
- Unit
- mcg
- Administration Route
- โ
- Frequency
- โ
- Last updated
- 8/23/2026
- Targets
- Myostatin (GDF8)Activin A
Overview
Isoform of follistatin that binds myostatin/activin. Gene-therapy and research-peptide forms exist; no FDA-approved follistatin drug. WADA prohibits myostatin inhibitors (S4).
Protocol
- Dosage Range
- Per research protocol
- Frequency
- โ
- Cycle
- โ
- Administration Route
- โ
- Reconstitution Guide
- โ
Science
Mechanism of Action
Binds and neutralizes TGF-ฮฒ superfamily ligands (myostatin, activin A), removing inhibition of skeletal-muscle growth in animal models.
Targets
Myostatin (GDF8)Activin A
Studies
- Follistatin and muscle massโ Journal/year not available
Benefits
Myostatin-pathway researchMuscle-hypertrophy models
Potential Side Effects
- Unknown human peptide-vial safety
- Theoretical activin-related effects
References
- PMID 11342534External link ยท Year โ
- WADA Prohibited List 2026External link ยท Year โ